Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
21.51
+0.16 (0.75%)
At close: Oct 30, 2026, 4:00 PM EDT
21.48
-0.03 (-0.15%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $23.43. The average 1-year stock price forecast is 8.93% higher than the current stock price, while the lowest is $20 (-7.02%) and the highest is $27 (+25.52%).
Price Target: $23.43 (+8.93%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 4 | 4 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 5 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Maintains $21 → $24 | Buy | Maintains | $21 → $24 | +11.58% | Oct 29, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $22 → $24 | Buy | Reiterates | $22 → $24 | +11.58% | Oct 22, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $27 | Buy | Initiates | $27 | +25.52% | Sep 23, 2026 |
| Barclays | Barclays | Buy Reiterates $20 | Buy | Reiterates | $20 | -7.02% | Sep 21, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $23 | Buy | Reiterates | $23 | +6.93% | Sep 17, 2026 |
Financial Forecast
Revenue This Year
3.16B
from 3.02B
Increased by 4.73%
Revenue Next Year
3.46B
from 3.16B
Increased by 9.36%
EPS This Year
1.03
from 0.83
Increased by 24.10%
EPS Next Year
1.21
from 1.03
Increased by 17.13%
EPS and Forward PE are based on non-GAAP adjusted numbers.